Vitamin D: Pharmacokinetics and Safety When Used in Conjunction with the Pharmaceutical Drugs Used in Cancer Patients: A Systematic Review

Cancers

Deborah A. Kennedy¹  Kieran Cooley¹  Becky Skidmore¹  Heidi Fritz¹  Tara Campbell¹ 

[1] Canadian College of Naturopathic Medicine, 1255 Sheppard Avenue East, Toronto, Ontario, M2K 1E2, Canada; E-Mails:

关键词: vitamin D;    calcitriol;    pharmacokinetics;    drug interactions;    systematic review;   

DOI  :  10.3390/cancers5010255

来源: mdpi

【 摘 要 】

Vitamin D has reported anti-cancer and anti-inflammatory properties modulated through gene transcription and non-genomic signaling cascades. The purpose of this review was to summarize the available research on interactions and pharmacokinetics between vitamin D and the pharmaceutical drugs used in patients with cancer. Hypercalcemia was the most frequently reported side effect that occurred in high dose calcitriol. The half-life of 25(OH)D₃ and/or 1,25(OH)₂D₃ was found to be impacted by cimetidine; rosuvastatin; prednisone and possibly some chemotherapy drugs. No unusual adverse effects in cancer patients; beyond what is expected from high dose 1,25(OH)₂D₃ supplementation, were revealed through this review. While sufficient evidence is lacking, supplementation with 1,25(OH)₂D₃ during chemotherapy appears to have a low risk of interaction. Further interactions with vitamin D₃ have not been studied.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.